272 related articles for article (PubMed ID: 37327781)
1. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients.
Diray-Arce J; Fourati S; Doni Jayavelu N; Patel R; Maguire C; Chang AC; Dandekar R; Qi J; Lee BH; van Zalm P; Schroeder A; Chen E; Konstorum A; Brito A; Gygi JP; Kho A; Chen J; Pawar S; Gonzalez-Reiche AS; Hoch A; Milliren CE; Overton JA; Westendorf K; ; Cairns CB; Rouphael N; Bosinger SE; Kim-Schulze S; Krammer F; Rosen L; Grubaugh ND; van Bakel H; Wilson M; Rajan J; Steen H; Eckalbar W; Cotsapas C; Langelier CR; Levy O; Altman MC; Maecker H; Montgomery RR; Haddad EK; Sekaly RP; Esserman D; Ozonoff A; Becker PM; Augustine AD; Guan L; Peters B; Kleinstein SH
Cell Rep Med; 2023 Jun; 4(6):101079. PubMed ID: 37327781
[TBL] [Abstract][Full Text] [Related]
2. Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality.
Gygi JP; Maguire C; Patel RK; Shinde P; Konstorum A; Shannon CP; Xu L; Hoch A; Jayavelu ND; Haddad EK; ; Reed EF; Kraft M; McComsey GA; Metcalf JP; Ozonoff A; Esserman D; Cairns CB; Rouphael N; Bosinger SE; Kim-Schulze S; Krammer F; Rosen LB; van Bakel H; Wilson M; Eckalbar WL; Maecker HT; Langelier CR; Steen H; Altman MC; Montgomery RR; Levy O; Melamed E; Pulendran B; Diray-Arce J; Smolen KK; Fragiadakis GK; Becker PM; Sekaly RP; Ehrlich LI; Fourati S; Peters B; Kleinstein SH; Guan L
J Clin Invest; 2024 May; 134(9):. PubMed ID: 38690733
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study.
;
Sci Immunol; 2021 Aug; 6(62):. PubMed ID: 34376480
[TBL] [Abstract][Full Text] [Related]
4. Multi-omic profiling reveals early immunological indicators for identifying COVID-19 Progressors.
Drake KA; Talantov D; Tong GJ; Lin JT; Verheijden S; Katz S; Leung JM; Yuen B; Krishna V; Wu MJ; Sutherland AM; Short SA; Kheradpour P; Mumbach MR; Franz KM; Trifonov V; Lucas MV; Merson J; Kim CC;
Clin Immunol; 2023 Nov; 256():109808. PubMed ID: 37852344
[TBL] [Abstract][Full Text] [Related]
5. Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study.
Hu Z; van der Ploeg K; Chakraborty S; Arunachalam PS; Mori DAM; Jacobson KB; Bonilla H; Parsonnet J; Andrews JR; Holubar M; Subramanian A; Khosla C; Maldonado Y; Hedlin H; de la Parte L; Press K; Ty M; Tan GS; Blish C; Takahashi S; Rodriguez-Barraquer I; Greenhouse B; Butte AJ; Singh U; Pulendran B; Wang TT; Jagannathan P
Elife; 2022 Oct; 11():. PubMed ID: 36239699
[TBL] [Abstract][Full Text] [Related]
6. Integrated longitudinal multi-omics study identifies immune programs associated with COVID-19 severity and mortality in 1152 hospitalized participants.
Gygi JP; Maguire C; Patel RK; Shinde P; Konstorum A; Shannon CP; Xu L; Hoch A; Jayavelu ND; Network I; Haddad EK; Reed EF; Kraft M; McComsey GA; Metcalf J; Ozonoff A; Esserman D; Cairns CB; Rouphael N; Bosinger SE; Kim-Schulze S; Krammer F; Rosen LB; van Bakel H; Wilson M; Eckalbar W; Maecker H; Langelier CR; Steen H; Altman MC; Montgomery RR; Levy O; Melamed E; Pulendran B; Diray-Arce J; Smolen KK; Fragiadakis GK; Becker PM; Augustine AD; Sekaly RP; Ehrlich LIR; Fourati S; Peters B; Kleinstein SH; Guan L
bioRxiv; 2023 Nov; ():. PubMed ID: 37986828
[TBL] [Abstract][Full Text] [Related]
7. Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence.
Gisby JS; Buang NB; Papadaki A; Clarke CL; Malik TH; Medjeral-Thomas N; Pinheiro D; Mortimer PM; Lewis S; Sandhu E; McAdoo SP; Prendecki MF; Willicombe M; Pickering MC; Botto M; Thomas DC; Peters JE
Nat Commun; 2022 Dec; 13(1):7775. PubMed ID: 36522333
[TBL] [Abstract][Full Text] [Related]
8. Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19.
Wongvibulsin S; Garibaldi BT; Antar AAR; Wen J; Wang MC; Gupta A; Bollinger R; Xu Y; Wang K; Betz JF; Muschelli J; Bandeen-Roche K; Zeger SL; Robinson ML
Ann Intern Med; 2021 Jun; 174(6):777-785. PubMed ID: 33646849
[TBL] [Abstract][Full Text] [Related]
9. Relationship of Heterologous Virus Responses and Outcomes in Hospitalized COVID-19 Patients.
Rosenberg-Hasson Y; Holmes TH; Diray-Arce J; Chen J; Kellogg R; Snyder M; Becker PM; Ozonoff A; Rouphael N; Reed EF; ; Maecker HT
J Immunol; 2023 Oct; 211(8):1224-1231. PubMed ID: 37756530
[TBL] [Abstract][Full Text] [Related]
10. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study.
Ozonoff A; Schaenman J; Jayavelu ND; Milliren CE; Calfee CS; Cairns CB; Kraft M; Baden LR; Shaw AC; Krammer F; van Bakel H; Esserman DA; Liu S; Sesma AF; Simon V; Hafler DA; Montgomery RR; Kleinstein SH; Levy O; Bime C; Haddad EK; Erle DJ; Pulendran B; Nadeau KC; Davis MM; Hough CL; Messer WB; Higuita NIA; Metcalf JP; Atkinson MA; Brakenridge SC; Corry D; Kheradmand F; Ehrlich LIR; Melamed E; McComsey GA; Sekaly R; Diray-Arce J; Peters B; Augustine AD; Reed EF; Altman MC; Becker PM; Rouphael N;
EBioMedicine; 2022 Sep; 83():104208. PubMed ID: 35952496
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
13. Short-term predictor for COVID-19 severity from a longitudinal multi-omics study for practical application in intensive care units.
Kugler S; Hahnefeld L; Kloka JA; Ginzel S; Nürenberg-Goloub E; Zinn S; Vehreschild MJ; Zacharowski K; Lindau S; Ullrich E; Burmeister J; Kohlhammer J; Schwäble J; Gurke R; Dorochow E; Bennett A; Dauth S; Campe J; Knape T; Laux V; Kannt A; Köhm M; Geisslinger G; Resch E; Behrens F
Talanta; 2024 Feb; 268(Pt 1):125295. PubMed ID: 37866305
[TBL] [Abstract][Full Text] [Related]
14. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
Front Immunol; 2021; 12():700921. PubMed ID: 34539631
[TBL] [Abstract][Full Text] [Related]
15. Multi-omic and comparative analyses revealed monocyte-derived alpha-defensin-1 correlated with COVID-19 severity and inhibited SARS-CoV-2 infection.
Qian X; Wu B; Chen X; Peng H; Liu M; Tang H; Xu Z; Xu C; Qi Z
J Med Virol; 2023 Jun; 95(6):e28845. PubMed ID: 37254949
[TBL] [Abstract][Full Text] [Related]
16. Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study.
Byeon SK; Madugundu AK; Garapati K; Ramarajan MG; Saraswat M; Kumar-M P; Hughes T; Shah R; Patnaik MM; Chia N; Ashrafzadeh-Kian S; Yao JD; Pritt BS; Cattaneo R; Salama ME; Zenka RM; Kipp BR; Grebe SKG; Singh RJ; Sadighi Akha AA; Algeciras-Schimnich A; Dasari S; Olson JE; Walsh JR; Venkatakrishnan AJ; Jenkinson G; O'Horo JC; Badley AD; Pandey A
Lancet Digit Health; 2022 Sep; 4(9):e632-e645. PubMed ID: 35835712
[TBL] [Abstract][Full Text] [Related]
17. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.
LaVergne SM; Stromberg S; Baxter BA; Webb TL; Dutt TS; Berry K; Tipton M; Haberman J; Massey BR; McFann K; Alnachoukati O; Zier L; Heacock T; Ebel GD; Henao-Tamayo M; Dunn J; Ryan EP
BMC Infect Dis; 2021 Jul; 21(1):677. PubMed ID: 34256735
[TBL] [Abstract][Full Text] [Related]
18. Amino Acid Metabolism is Significantly Altered at the Time of Admission in Hospital for Severe COVID-19 Patients: Findings from Longitudinal Targeted Metabolomics Analysis.
Ansone L; Briviba M; Silamikelis I; Terentjeva A; Perkons I; Birzniece L; Rovite V; Rozentale B; Viksna L; Kolesova O; Klavins K; Klovins J
Microbiol Spectr; 2021 Dec; 9(3):e0033821. PubMed ID: 34878333
[TBL] [Abstract][Full Text] [Related]
19. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19.
Bernardes JP; Mishra N; Tran F; Bahmer T; Best L; Blase JI; Bordoni D; Franzenburg J; Geisen U; Josephs-Spaulding J; Köhler P; Künstner A; Rosati E; Aschenbrenner AC; Bacher P; Baran N; Boysen T; Brandt B; Bruse N; Dörr J; Dräger A; Elke G; Ellinghaus D; Fischer J; Forster M; Franke A; Franzenburg S; Frey N; Friedrichs A; Fuß J; Glück A; Hamm J; Hinrichsen F; Hoeppner MP; Imm S; Junker R; Kaiser S; Kan YH; Knoll R; Lange C; Laue G; Lier C; Lindner M; Marinos G; Markewitz R; Nattermann J; Noth R; Pickkers P; Rabe KF; Renz A; Röcken C; Rupp J; Schaffarzyk A; Scheffold A; Schulte-Schrepping J; Schunk D; Skowasch D; Ulas T; Wandinger KP; Wittig M; Zimmermann J; Busch H; Hoyer BF; Kaleta C; Heyckendorf J; Kox M; Rybniker J; Schreiber S; Schultze JL; Rosenstiel P; ;
Immunity; 2020 Dec; 53(6):1296-1314.e9. PubMed ID: 33296687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
